urticaria (hives)

From Aaushi
Jump to navigation Jump to search

Introduction

Wheal (swelling) & flare (redness) response to histamine release.

Classification

  • acute: daily for < 6 weeks
  • chronic: daily for > 6 weeks

Etiology

Epidemiology

  • occurs in 20-25% of population at some time[26]
  • chronic urticaria (daily for > 6 weeks)
    • more common in adults
    • female:male ratio is 2:1

Pathology

Clinical manifestations

  • wheal (swelling) & flare (redness)
  • elevated, well circumscribed, erythematous, edematous, pruritic lesions
  • angioedema of the face, hands & feet (not lips) in majority of patients[26]
  • in acute urticaria, lesions are transient
    • lesions appear quickly
    • episodes generally resolve spontaneously within 24-48 hours; most last 2-18 hours
    • urticaria due to insect bite or sting can last > 24 hours[26]
    • lesions generally resolve without scarring or discoloration
    • lesions may recur in a new area with little or no period of remission[4]
  • chronic idiopathic urticaria
    • recurrent episodes of urticaria lasting > 6 weeks
      • episodes occur immediately & resolve quickly[26]
    • episodes of angioedema generally occur, either alone or concurrently
    • 40% still have urticaria after 10 years
  • tiny pinpoint hives are characteristic of cholinergic urticaria[26]

* images[15][16]

Laboratory

Radiology

  • chest X-ray for urticaria of more than 6 weeks duration

Complications

  • angioedema of the lips
    • patients with urticarial lesions around the mouth should be evaluated & monitored for airway obstruction
  • autoimmune disease may occur up to 10 years after onset of chronic urticaria - probably related more to a common etiology rather than a direct complication[8]

Differential diagnosis

(lesions lasting > 24 hours)

Management

More general terms

More specific terms

Additional terms

References

  1. Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook, Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 829-39
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 910-12
  3. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 25-27
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018, 2022.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  5. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 322
  6. 6.0 6.1 Tarbox JA et al. Utility of routine laboratory testing in management of chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2011 Sep; 107:239 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21875543
  7. 7.0 7.1 Saini S et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine- refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011 Sep; 128:567 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21762974
    Maurer M et al Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med. February 24, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23432142 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1215372
  8. 8.0 8.1 8.2 8.3 Journal Watch, May 11, 2012 Massachusetts Medical Society
    Confino-Cohen R et al. Chronic urticaria and autoimmunity: Associations found in a large population study. J Allergy Clin Immunol 2012 May; 129:1307 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22336078
  9. Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. J Am Acad Dermatol. 2010 Apr;62(4):541-55 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20227576
    Peroni A, Colato C, Zanoni G, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol. 2010 Apr;62(4):557-70 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20227577
  10. Zuberbier T, Asero R, Bindslev-Jensen C et al EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct;64(10):1427-43 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19772513
  11. 11.0 11.1 11.2 Rajan JP et al. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticarial. J Allergy Clin Immunol Pract 2014 Mar/Apr; 2:168 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24607044 <Internet> http://www.sciencedirect.com/science/article/pii/S2213219813003929
  12. 12.0 12.1 Saini SS et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study. J Invest Dermatol 2015 Jan; 135:67 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25046337
  13. 13.0 13.1 Spector SL, Tan RA Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007 Aug;99(2):190-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17718108
  14. Zuberbier T, Bindslev-Jensen C, Canonica W et al EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006 Mar;61(3):316-20. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16436140
    Zuberbier T, Asero R, Bindslev-Jensen C et al EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009 Oct;64(10):1417-26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19772512
  15. 15.0 15.1 Wong HK, Elston DM (images) Medscape: Urticaria http://emedicine.medscape.com/article/762917-overview
    Wong HK, Elston DM (images) Medscape: Acute Urticaria http://emedicine.medscape.com/article/137362-overview
  16. 16.0 16.1 DermNet NZ. Urticaria (images) http://www.dermnetnz.org/reactions/urticaria.html
  17. American Academy of Dermatology: Hives (image) https://www.aad.org/public/diseases/itchy-skin/hives
  18. Micheletti R, Rosenbach M. An approach to the hospitalized patient with urticaria and fever. Dermatol Ther. 2011 Mar-Apr;24(2):187-95 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21410608
  19. 19.0 19.1 Barniol C et al. Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: A randomized double-blind clinical trial. Ann Emerg Med 2017 May 3; PMID: https://www.ncbi.nlm.nih.gov/pubmed/28476259
  20. Bernstein JA, Lang DM, Khan DA et al The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270-7. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24766875
  21. 21.0 21.1 Liang SE, Hoffmann R, Peterson E et al. Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria. JAMA Dermatol 2018 Nov 21; 155:90. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30476976 https://jamanetwork.com/journals/jamadermatology/fullarticle/2715087
  22. 22.0 22.1 Maurer M, Gimenez-Arnau, Sussman G et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019 Oct 3; 381:1321 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31577874 https://www.nejm.org/doi/10.1056/NEJMoa1900408
  23. 23.0 23.1 Shaker M, Oppenheimer J, Wallace D et al. Optimizing value in the evaluation of chronic spontaneous urticaria: A cost-effectiveness analysis. J Allergy Clin Immunol Pract 2019 Nov 18; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31751758 https://www.sciencedirect.com/science/article/abs/pii/S2213219819309389
  24. 24.0 24.1 Abella BS et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: A phase III randomized controlled noninferiority trial. Ann Emerg Med 2020 Oct; 76:489 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32653333 https://www.annemergmed.com/article/S0196-0644(20)30396-6/fulltext
  25. 25.0 25.1 25.2 Nochaiwong S, Chuamanochan M, Ruengorn C et al Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria. A Systematic Review and Network Meta-analysis. JAMA Dermatol. Published online August 25, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34431983 https://jamanetwork.com/journals/jamadermatology/fullarticle/2783033
  26. 26.00 26.01 26.02 26.03 26.04 26.05 26.06 26.07 26.08 26.09 26.10 26.11 James W Fast Five Quiz: Urticaria (Hives) Medscape. December 12, 2022 https://reference.medscape.com/viewarticle/984987
  27. NEJM Knowledge+ Hematology
  28. 28.0 28.1 NEJM Knowledge+ Dermatology
  29. 29.0 29.1 29.2 29.3 29.4 NEJM Knowledge+ Allergy/Immunology
  30. 30.0 30.1 Davis MD, van der Hilst JC. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract. 2018;6:1162-70. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29871797
  31. 31.0 31.1 Khan DA, Kocaturk E, Bauer A, Aygoren-Pursun E. What's new in the treatment of urticaria and angioedema. J Allergy Clin Immunol Pract. 2021;9:2170-2184. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34112473
  32. Saini S, Shams M, Bernstein JA, et al. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8:1866-1874. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32298850

Patient information

urticaria patient information